trial

A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia

NCTId NCT00642369
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 60 (actual)
Sponsored by Guang Dong Provincial Mental Health Institute
Primary completion 2009-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2008-03
Primary completion
2009-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
QuetiapineHaloperidol

Sponsors

Guang Dong Provincial Mental Health InstituteLead Sponsor

Investigators

1
Zhang Bin, Ph. DPrincipal Investigator

Sites

1 total
Guangzhou, China

Facts & assertions

4 sourced
Enrollment
60
Phase
NA
Primary Completion Date
2009-07
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
Haloperidol
drug
lead_sponsor
Guang Dong Provincial Mental Health Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Zhang Bin, Ph. D
person